CD200 and cancer: After gefitinib treatment, the number of viable PC9-RFP cells was significantly lower when the cancer cells were cocultured with CAF621-CD200+ compared to when they were cocultured with control CAF621 cells (19.4% vs. 28.1%, P < 0.05, Fig. 5F).